Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down

Apellis Pharmaceuticals (APLS) reported first-quarter 2025 loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 36 cents. The company had incurred a loss of 54 cents in the year-ago quarter.Total revenues in the first quarter amounted to $166.8 million and missed the Zacks Consensus Estimate of$192 million. In the year-ago quarter, the company had reported revenues of $172.3 million.The top line lost 3% year over year as sales of Syfovre (pegcetacoplan injection) were impacted b ...